TR
Therapeutic Areas
Kinoxis Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KNX100 | Agitation and aggression associated with dementia | Phase 2 |
| KNX101 | Acute and chronic pain | Preclinical/IND‑enabling |
| KNX200 series | Stress adaptation, emotional regulation, nociception (oxytocin‑receptor partial agonists) | Preclinical |
Leadership Team at Kinoxis Therapeutics
HA
Hugh Alsop
Chief Executive Officer
MB
Michael Bowen
Chief Scientific Officer
TA
Tiina Ahveninen
Vice President, Clinical Research
CJ
Cameron Jones
Chief Financial Officer & Company Secretary
PD
Peter Devine
Chair
JC
Julie Cairney
Non‑Executive Director
KN
Kathy Nielsen
Non‑Executive Director